Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

More than 69.2 million FDA-approved weight-loss prescriptions were dispensed in the U.S. from July 2017 through February 2024 ...

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...

A major new study has highlighted significant health risks associated with popular weight loss injections such as Ozempic, ...

However, studies have shown these risks in high ... strokes and a BMI of 27 kg/m² or higher. Learn more about Wegovy for weight loss. Ozempic, also semaglutide, is in the glucagon-like peptide ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...

The study published in Nature Medicine is unique in its scope, marking a milestone in the study of new-generation weight-loss drugs such as Ozempic, Wegovy and Mounjaro, which have already somewhat ...

News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...